Brain cell discoveries reshape understanding of psychiatric disorders
Reports and Proceedings
In honor of Alzheimer's Awareness Month, we’re exploring the science and stories surrounding Alzheimer’s disease.
Updates every hour. Last Updated: 28-Oct-2025 10:11 ET (28-Oct-2025 14:11 GMT/UTC)
A trailblazing Genomic Press interview with Dr. Bruce M. Cohen explores how cutting-edge brain cell technology is providing revolutionary new information on the biological origins of psychiatric disorders. Among these findings, the Harvard professor discusses discoveries on mitochondrial dysfunction that are opening novel therapeutic pathways for schizophrenia, bipolar disorder, and Alzheimer disease. In addition, his advocacy for evidence-based diagnostic models challenges century-old psychiatric frameworks, proposing specific dimensional approaches that better capture the complexities of causes, presentations, and outcomes of mental illnesses.
The increased prevalence of Alzheimer's disease (AD) in women is likely not driven by sex differences in healthy brain aging, a study suggests.
There may be a way to protect brain energy to preserve cognition — and the secret could lie on your plate. Think fish and seafood, meat, non-starchy vegetables, berries, nuts, seeds, eggs and even high-fat dairy products.
University of Missouri researchers are now testing just how powerful these foods can be. They’ve found that a high fat, low carb diet — known as the ketogenic diet — may not only preserve brain health but also stop or slow the signs of cognitive decline for those at higher risk of developing Alzheimer’s disease.
The prevalence of Alzheimer disease (AD) is approximately two times higher in African Americans (AA) compared to White/European-ancestry (EA) individuals living in the U.S. Some of this is due to social determinants of health such as disparities in health care access and quality of education, biases in testing and higher rates of AD risk factors such as cardiovascular disease and diabetes in those who identify as African American.
Although many studies have examined differences in gene expression (measure of the amount of protein encoded by a gene) in brain tissue from AD cases and controls in EA or mixed ancestry cohorts, the number of AA individuals in these studies was unspecified or too small to identify significant findings within this group alone.
In the largest AD study conducted in brain tissue from AA donors, researchers from Boston University Chobanian & Avedisian School of Medicine have identified many genes, a large portion of which had not previously been implicated in AD by other genetic studies, to be significantly more or less active in tissue from AD cases compared to controls. The most notable finding was a 1.5 fold higher level of expression of the ADAMTS2 gene in brain tissue from those with autopsy-confirmed AD.